胃间质瘤术前辅助伊马替尼治疗的临床意义

doi:10.11904/j.issn.1002-3070.2015.05.009

实用肿瘤学杂志 ›› 2015, Vol. 29 ›› Issue (5): 424-427.doi: 10.11904/j.issn.1002-3070.2015.05.009

胃间质瘤术前辅助伊马替尼治疗的临床意义

裴文晔¹, 张峻², 闫芙军¹, 王萍¹, 赵岩²

1.辽宁省肿瘤医院门诊手术室(沈阳 110042);
2.辽宁省肿瘤医院胃外科

收稿日期:2015-07-28 出版日期:2015-10-28 发布日期:2015-10-30
通讯作者: 赵岩,E-mail:zhaoyan@medmail.com.cn
作者简介:裴文晔,女,(1968-),本科,主管护师,从事临床护理的研究

Clinical significance of preoperative imatinib therapy in stomach gastrointestinal stromal tumors

PEI Wenye¹, ZHANG Jun², YAN Fujun¹, WANG Ping¹, ZHAO Yan²

1.Department of Outpatient Operation,Liaoning Cancer Hospital & Institute,Shenyang 110042,China;
2.Department of Gastric Surgery,Liaoning Cancer Hospital & Institute

Received:2015-07-28 Online:2015-10-28 Published:2015-10-30

摘要/Abstract

摘要： 目的胃肠间质瘤(Gastrointestinal stromal tumor,GIST)是胃肠道最常见的间叶来源性肿瘤,根治性手术是GIST获得治愈的唯一希望。为了提高手术根治性切除率,降低手术风险,提高生活质量,伊马替尼(IM)开始被尝试应用于GIST的术前治疗。方法本研究回顾8例GIST术前辅助治疗后手术的诊疗经过。IM每日一次400mg口服,严密随访,评价疗效,并通过多学科讨论确定手术时机。用药时间12周~40周。对IM术前辅助治疗的临床疗效和安全性予以评价。结果术前治疗部分缓解率62.5%。本组病例未出现不可耐受的不良反应。全部病例均获R₀切除,未出现术中肿瘤破裂。术后恢复顺利。结论针对进展期胃部巨大GIST及近贲门区GIST,在多学科诊疗团队的监护下,术前辅助IM治疗安全有效,值得临床推广应用。

关键词: 胃肠间质瘤, 伊马替尼, 术前治疗, 多学科协作组

Abstract: Objective Gastrointestinal stromal tumor(GIST)is a rare mesenchymal tumor from gastrointestinal tract,and surgery remains the only curative treatment.In order to improve the outcome of surgical treatment,reduce the risk of surgery,and increase the quality of life,preoperative imatinib(IM)treatment for GIST is investigated.Methods We retrospectively studied the multidisciplinary team model treatments for 8 GIST cases receiving preoperative IM treatment.The cases were prescribed IM of 400mg daily for 12 to 40 weeks and extensively followed until surgery was considered feasibleg.The clinical significance and safety profile were analyzed.Results Partial responsive rate was 62.5% in this study.There was no intolerable sever adverse effects by IM preoperative treatment.All the cases received R₀ dissection,with no intraoperative tumor rupture.The postoperative recovery was satisfied.Conclusion IM preoperative treatment brings significant clinical benefit to large stomach GISTs and cardiac region GISTs.The preoperative treatment should be monitored carefully under a multidisciplinary team.Preoperative IM treatment is an evocative treatment strategy for high risk GIST.

Key words: Gastrointestinal stromal tumor(GIST), Imatinib, Preoperative treatment, Multidisciplinary team(MDT)

中图分类号:

R735.2

裴文晔, 张峻, 闫芙军, 王萍, 赵岩. 胃间质瘤术前辅助伊马替尼治疗的临床意义[J]. 实用肿瘤学杂志, 2015, 29(5): 424-427.

PEI Wenye, ZHANG Jun, YAN Fujun, WANG Ping, ZHAO Yan. Clinical significance of preoperative imatinib therapy in stomach gastrointestinal stromal tumors[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(5): 424-427.

参考文献

1 Corless CL,Barnett CM,Heinrich MC.Gastrointestinal stromal tumours:origin and molecular oncology[J].Nat Rev Cancer,2011,11(12):865-878.
2 Zaydfudim V,Okuno SH,Que FG,et al.Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors[J].J Surg Res,2012,177(2):248-254.
3 Eisenberg BL.The SSG XVIII/AIO trial:results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors[J].Am J Clin Oncol,2013,36(1):89-90.
4 Corless CL,Ballman KV,Antonescu CR,et al.Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor:the ACOSOG Z9001 trial[J].J Clin Oncol,2014,32(15):1563-1570.
5 Lang I,Hitre E,Horvath Z,et al.Case 3.Resection of originally inoperable liver metastases of gastrointestinal stromal tumor after imatinib mesylate therapy[J].J Clin Oncol,2003,21(18):3538-3540.
6 Fujimoto Y,Akiyoshi T,Konishi T,et al.Laparoscopic sphincter-preserving surgery(intersphincteric resection)after neoadjuvant imatinib treatment for gastrointestinal stromal tumor(GIST)of the rectum[J].Int J Colorectal Dis,2014,29(1):111-116.
7 Wang D,Zhang Q,Blanke CD,et al.Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors:long-term follow-up results of Radiation Therapy Oncology Group 0132[J].Ann Surg Oncol,2012,19(4):1074-1080.
8 Pandey R,Kochar R.Management of gastrointestinal stromal tumors:looking beyond the knife.An update on the role of adjuvant and neoadjuvant imatinib therapy[J].J Gastrointest Cancer,2012,43(4):547-552.
9 Koontz MZ,Visser BM,Kunz PL.Neoadjuvant imatinib for borderline resectable GIST[J].J Natl Compr Canc Netw,2012,10(12):1477-1482.
10 Blesius A,Cassier PA,Bertucci F,et al.Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial[J].BMC Cancer,2011,11:72.
11 Kang GH,Son MW,Han SW,et al.Clinicopathologic change of gastrointestinal stromal tumor after neoadjuvant imatinib followed by surgical resection[J].J Korean Surg Soc,2012,82(2):120-124.
12 Eisenberg BL,Harris J,Blanke CD,et al.Phase II trial of neoadjuvant/adjuvant imatinib mesylate(IM)for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor(GIST):early results of RTOG 0132/ACRIN 6665[J].J Surg Oncol,2009,99(1):42-47.
13 Andtbacka RH,Ng CS,Scaife CL,et al.Surgical resection of gastrointestinal stromal tumors after treatment with imatinib[J].Ann Surg Oncol,2007,14(1):14-24.
14 Bednarski BK,Araujo DM,Yi M,et al.Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors[J].Ann Surg Oncol,2014,21(8):2499-2505.
15 CSCO胃肠间质瘤专家委员会.中国胃肠间质瘤诊断治疗共识(2013年版)[J].临床肿瘤学杂志,2013,18(11):1025-1032.
16 Jakob J,Mussi C,Ronellenfitsch U,et al.Gastrointestinal stromal tumor of the rectum:results of surgical and multimodality therapy in the era of imatinib[J].Ann Surg Oncol,2013,20(2):586-592.
17 Tielen R,Verhoef C,van Coevorden F,et al.Surgical management of rectal gastrointestinal stromal tumors[J].J Surg Oncol,2013,107(4):320-323.

[1]	吴非, 战学雷, 张景波, 马永权, 何立伟, 喻航. 胃肠间质瘤32例临床分析[J]. 实用肿瘤学杂志, 2011, 25(5): 439-441.
[2]	程新宇, 孙洁, 王翠芳. p53、p21WAF-1和p63在胃肠间质瘤中表达的相互关系及意义[J]. 实用肿瘤学杂志, 2009, 23(5): 447-450.
[3]	杨琳, 谢榕, 林玉珍. 宫颈癌术前介入化疗治疗的临床意义[J]. 实用肿瘤学杂志, 2009, 23(4): 349-349.
[4]	赵小康;赵永明;蒋阳平;胡桂女. 16例胃肠间质瘤临床治疗[J]. 实用肿瘤学杂志, 2006, 20(01): 53-53,64.
[5]	张丽华;孙荣超;陈瑛. 胃肠道间质瘤临床病理分析[J]. 实用肿瘤学杂志, 2002, 16(04): 268-270,.

胃间质瘤术前辅助伊马替尼治疗的临床意义

Clinical significance of preoperative imatinib therapy in stomach gastrointestinal stromal tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价